Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Ioannis Pozios

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3462-9822; OpenAlex author ID A5015800882. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: none · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 1 paper

Papers 9

  1. Correction to: Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling. Co-author DOI 10.1007/s13402-025-01128-8↗
  2. Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144. Co-author DOI 10.1007/s00432-022-04518-9↗
  3. Targeting Interleukin-6/Glycoprotein-130 Signaling by Raloxifene or SC144 Enhances Paclitaxel Efficacy in Pancreatic Cancer. Last author DOI 10.3390/cancers15020456↗
  4. Thymidine phosphorylase induction by ionizing radiation antagonizes 5-fluorouracil resistance in human ductal pancreatic adenocarcinoma. First author DOI 10.1007/s00411-022-00962-w↗
  5. Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling. Co-author DOI 10.1007/s13402-020-00559-9↗
  6. Rethinking the TNM Classification Regarding Direct Lymph Node Invasion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14010201↗
  7. Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-018-2717-2↗
  8. Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma. First author DOI 10.1186/s12885-018-4973-6↗
  9. Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-017-2351-4↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hendrik Seeliger · 8 shared papers, 2017–2025 · strength 1.10
  2. Christiane J. Bruns · 7 shared papers, 2017–2025 · strength 0.92
  3. Nina A. Hering · 4 shared papers, 2021–2025 · strength 0.72
  4. Katharina Beyer · 4 shared papers, 2021–2023 · strength 0.63
  5. Lucas D. Lee · 3 shared papers, 2021–2025 · strength 0.51
  6. Peter Čamaj · 3 shared papers, 2017–2025 · strength 0.42
  7. Thomas Knösel · 4 shared papers, 2017–2023 · strength 0.40
  8. Georgios Antonios Margonis · 2 shared papers, 2021–2023 · strength 0.29
  9. Carsten Kamphues · 2 shared papers, 2021–2022 · strength 0.27
  10. Yue Zhao · 3 shared papers, 2017–2018 · strength 0.23
  11. Fiona Speichinger · 1 shared paper, 2021 · strength 0.12
  12. Mihnea Paul Dragomir · 1 shared paper, 2021 · strength 0.12
  13. Simon Schallenberg · 1 shared paper, 2021 · strength 0.12
  14. Florian Nino Loch · 1 shared paper, 2021 · strength 0.12
  15. Hanno Nieß · 1 shared paper, 2017 · strength 0.06
  16. Felix Popp · 1 shared paper, 2017 · strength 0.06
  17. Utz Settmacher · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.